Technology & Devices

Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer

SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …

Read More »

Dragonfly Collaborates with Merck to Develop Novel Drug Candidates for Solid Tumors Using Dragonfly’s TriNKET Platform

WALTHAM, Mass., Oct. 1, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to …

Read More »

FDA Authorizes Adaptive’s clonoSEQ Assay to Detect MRD in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies® announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo designation for the clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL) using DNA from a patient’s bone marrow sample. The clearance …

Read More »

Study Shows that Measuring MRD Negativity Using Adaptive’s Next-Generation Sequencing Platform is a Major Predictive Indicator in Multiple Myeloma

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies today announced that Blood, the Journal of the American Society of Hematology (ASH), published online an analysis of patient samples from the Intergroupe Francophone du Myéloma (IFM) 2009 trial. The analysis confirms the value of minimal residual disease (MRD) as a prognostic indicator in multiple myeloma (MM) measured …

Read More »

Quest Diagnostics Acquires PhenoPath, Broadening Access to Advanced Diagnostics

SECAUCUS, N.J. and SEATTLE, Sept. 27, 2018 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has acquired PhenoPath, a national provider of specialized anatomic pathology (AP) and related services. Based in Seattle, PhenoPath provides AP, molecular oncology and other services that complement and extend those of …

Read More »

Agilent to Expand Portfolio and Capabilities in Cell Analysis with Acquisition of ACEA Biosciences

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire privately-owned ACEA Biosciences Inc. (ACEA), a developer of cutting-edge cell analysis instruments for life science research and clinical diagnostics, for $250 million in cash. “Expanding our cell analysis footprint is a key strategic …

Read More »

Medtronic to Acquire Mazor Robotics in $1.64 Billion Deal

DUBLIN and CAESAREA, Israel – September 20, 2018 – Medtronic plc (NYSE:MDT), a global leader in medical technology, and Mazor Robotics (NASDAQ:MZOR, TASE:MZOR.TZ), a pioneer in the field of robotic guidance systems, today announced the companies have entered into a definitive merger agreement under which Medtronic will acquire all outstanding ordinary …

Read More »

Thermo Fisher Scientific Expands Genome Editing IP Portfolio

CARLSBAD, Calif., Sept. 18, 2018 /PRNewswire/ — Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the Broad Institute and ERS Genomics (foundational University of California IP) to bolster its genome editing intellectual property (IP) portfolio. Under the terms of the licenses, Thermo Fisher …

Read More »

ITM and Merck KGaA Sign Research Evaluation and Option Agreement to Develop Folate Receptor Targeted Radionuclide Therapy

GARCHING, Germany–(BUSINESS WIRE)–Isotopen Technologien München AG (ITM), a group of specialized radiopharmaceutical companies, announced today that it has signed a Research Evaluation and Option Agreement for a worldwide exclusive license with Merck KGaA, Darmstadt, Germany. Merck KGaA is a global leader for the development and manufacturing of active pharmaceutical ingredients …

Read More »

Natera and Bristol-Myers Squibb Partner to Investigate Signatera ctDNA Assay as a Potential Biomarker for Opdivo in a NSCLC Clinical Trial

SAN CARLOS, Calif., Sept. 13, 2018 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an agreement with Bristol-Myers Squibb to use Natera’s Signatera™ custom circulating tumor DNA (ctDNA) assay in a Phase 2 study in the adjuvant non-small cell lung cancer (NSCLC) setting. The study will use …

Read More »